« Previous Next » Clinical Oncology
Volume 21, Issue 5 , Page 425 , June 2009

Early Tolerability and Results of I¹²⁵ Permanent Prostate Brachytherapy in a Single UK Institution

Q. Ghafoor
- Department of Clinical Oncology, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
D.R. Ford
- Department of Clinical Oncology, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
L. Capaldi
- Department of Clinical Oncology, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
G.J. Heyes
- Department of Radiotherapy Physics, Medical Physics, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
R.M. Wyatt
- Department of Radiotherapy Physics, Medical Physics, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
A. Doherty
- Department of Urology, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
A. El-Modir
- Department of Clinical Oncology, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK

References

Michell DM, Mandell P, Bottomley D, et al. Report on the early efficacy and tolerability of I¹²⁵ permanent prostate brachytherapy from a UK multi-institutional database. Clin Oncol (R Coll Radiol). 2008;20:738–744
American Society for Therapeutic Radiology and Oncology . Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
- Full-Text PDF (875 KB)
Henderson A, Ismail AKA, Cunningham M, et al. Toxicity and early biochemical outcomes from 125iodine brachytherapy in the UK: a prospective study. Clin Oncol. 2004;16:95–104